Abbott Laboratories (NYSE:ABT) Stock Sold Rep. Julie Johnson

Posted by Brenda Bartman on Jun 25th, 2026

Representative Julie Johnson (Democratic-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on May 12th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 5/12/2026.

Abbott Laboratories Stock Down 0.1%

Shares of NYSE ABT opened at $90.46 on Thursday. The company has a market cap of $157.56 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 1.56 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm’s fifty day moving average is $89.39 and its 200 day moving average is $105.69. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $138.84.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Leerink Partners decreased their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. TD Cowen reduced their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Benchmark decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Stifel Nicolaus dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.30.

Check Out Our Latest Research Report on Abbott Laboratories

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: ALZpath signed a global licensing agreement with Abbott to advance a blood-based Alzheimer’s test, potentially expanding Abbott’s diagnostics pipeline and creating a new growth opportunity in a large, high-need market. Reuters article
Positive Sentiment: Coverage highlighting Abbott’s emerging-markets EPD momentum points to stronger demand for branded generics, biosimilars, and new approvals, which could support revenue growth in international markets. Yahoo Finance article
Positive Sentiment: MiniMed’s launch of Abbott’s Instinct sensors across European markets broadens adoption of Abbott diabetes technology and reinforces its connected-care ecosystem. Yahoo Finance article
Positive Sentiment: Recent commentary from Wall Street and stock-screening sites remains constructive, with Abbott described as a Dividend Aristocrat and a financially stable, long-term holding that continues to attract investor interest. Insider Monkey article
Neutral Sentiment: Abbott remains on investors’ radar after multiple articles noted heightened attention and favorable analyst sentiment, but these items are mainly sentiment-driven rather than new operating updates. Zacks article
Neutral Sentiment: Abbott was also featured as a durable dividend stock with an “ironclad moat,” reinforcing the case for stability and income, but not indicating a major near-term catalyst by itself. 247WallSt article
Negative Sentiment: Abbott is still dealing with legal overhang from the $495 million preterm baby formula verdict, as a Missouri appeals court declined to move the case to a higher court, leaving a potential liability issue unresolved. MSN article

Insiders Place Their Bets

In related news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Institutional Trading of Abbott Laboratories

Several institutional investors have recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.